A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control

Diabetes

Volumn 61, Issue 5, 2012, Pages 1263-1271

  Bhaskar, Vinay ^a   Goldfine, Ira D ^b   Bedinger, Daniel H ^a   Lau, Angela ^a   Kuan, Hua F ^a   Gross, Lisa M ^a   Handa, Masahisa ^a   Maddux, Betty A ^b   Watson, Susan R ^a   Zhu, Shirley ^a   Narasimha, Ajay J ^a   Levy, Raphael ^a   Webster, Lynn ^a   Wijesuriya, Sujeewa D ^a   Liu, Naichi ^a   Wu, Xiaorong ^a   Chemla Vogel, David ^a   Tran, Catarina ^a   Lee, Steve R ^a   Wong, Steve ^a   Wilcock, Diane ^a   White, Mark L ^a   Corbin, John A ^a   more..

^a XOMA Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY XMETA; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOPHYSICS; CANCER CELL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELLS, CULTURED; CHO CELLS; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MICE; MICE, INBRED ICR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84860577150     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1578     Document Type: Article

References (50)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
2. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976;294:739-745
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607 (Pubitemid 19004941)
4. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003; 5:364-371 (Pubitemid 38898895)
5. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303 (Pubitemid 38680631)
6. Kolterman OG, Insel J, Saekow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 1980;65:1272-1284 (Pubitemid 10122368)
7. Reaven GM, Olefsky JM. The role of insulin resistance in the pathogenesis of diabetes mellitus. Adv Metab Disord 1978;9:313-331
8. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-929
9. Lyssenko V, Almgren P, Anevski D, et al.; Botnia study group. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166-174 (Pubitemid 40105109)
10. Chen YD, Jeng CY, Hollenbeck CB, Wu MS, Reaven GM. Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes. J Clin Invest 1988;82:21-25 (Pubitemid 18262493)
11. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-915
12. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992 (Pubitemid 24015042)
13. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
14. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96 (Pubitemid 43278292)
15. Asano T, Fujishiro M, Kushiyama A, et al. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol Pharm Bull 2007;30:1610-1616 (Pubitemid 47403232)
16. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004;10:65-71 (Pubitemid 41825486)
17. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 2010;1:68-75
18. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-49
19. Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Longacting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 2011;7:61-74
20. Niswender KD. Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med 2011;123:17-26
21. Goldfine ID, Roth RA. Monoclonal antibodies to the insulin receptor as probes of insulin receptor structure and function. Horiz Biochem Biophys 1986;8:471-502
22. Soos MA, Siddle K, Baron MD, et al. Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem J 1986;235:199-208 (Pubitemid 16041992)
23. Siddle K, Soos MA, O'Brien RM, Ganderton RH, Taylor R. Monoclonal antibodies as probes of the structure and function of insulin receptors. Biochem Soc Trans 1987;15:47-51 (Pubitemid 17010253)
24. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore) 2009;88:141-153
25. Le Marchand-Brustel Y, Gorden P, Flier JS, Kahn CR, Freychet P. Antiinsulin receptor antibodies inhibit insulin binding and stimulate glucose metabolism in skeletal muscle. Diabetologia 1978;14:311-317 (Pubitemid 8321892)
26. De Pirro R, Roth RA, Rossetti L, Goldfine ID. Characterization of the serum from a patient with insulin resistance and hypoglycemia. Evidence for multiple populations of insulin receptor antibodies with different receptor binding and insulin-mimicking activities. Diabetes 1984;33:301-304 (Pubitemid 14196224)
27. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002;81: 87-100 (Pubitemid 34218566)
28. Brunetti A, Maddux BA, Wong KY, et al. Monoclonal antibodies to the human insulin receptor mimic a spectrum of biological effects in transfected 3T3/HIR fibroblasts without activating receptor kinase. Biochem Biophys Res Commun 1989;165:212-218 (Pubitemid 20012477)
29. Zick Y, Rees-Jones RW, Taylor SI, Gorden P, Roth J. The role of antireceptor antibodies in stimulating phosphorylation of the insulin receptor. J Biol Chem 1984;259:4396-4400 (Pubitemid 14127804)
30. Taylor SI, Grunberger G, Marcus-Samuels B, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 1982;307:1422-1426 (Pubitemid 13234015)
31. Chen CR, McLachlan SM, Rapoport B. Suppression of thyrotropin receptor constitutive activity by a monoclonal antibody with inverse agonist activity. Endocrinology 2007;148:2375-2382 (Pubitemid 46997086)
32. Peter JC, Eftekhari P, Billiald P, Wallukat G, Hoebeke J. scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor. J Biol Chem 2003;278:36740-36747 (Pubitemid 37140007)
33. Josephson K, Jones BC, Walter LJ, DiGiacomo R, Indelicato SR, Walter MR. Noncompetitive antibody neutralization of IL-10 revealed by protein engineering and x-ray crystallography. Structure 2002;10:981-987 (Pubitemid 34790268)
34. Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM. Allosteric effects of a monoclonal antibody against thrombin exosite II. Biochemistry 1998;37:15057-15065 (Pubitemid 28503233)
35. Cazorla M, Arrang JM, Prémont J. Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br J Pharmacol 2011;162:947-960
36. Root-Bernstein R, Vonck J. Glucose binds to the insulin receptor affecting the mutual affinity of insulin and its receptor. Cell Mol Life Sci 2009;66: 2721-2732
37. De Meyts P, Gauguin L, Svendsen AM, et al. Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors. Ann N Y Acad Sci 2009;1160:45-53
38. De Meyts P. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? Trends Biochem Sci 2008;33:376-384
39. Jensen M, Hansen B, De Meyts P, Schäffer L, Ursø B. Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J Biol Chem 2007;282: 35179-35186 (Pubitemid 350232483)
40. A. Aa CFB. D.R. Burton, J.K. Scott, G.J. Silverman: Phage Display: A Laboratory Manual. Plainview, NY, Cold Spring Harbor Laboratory Press, 2001
41. Aitken R. Methods in Molecular Biology. In Antibody phage display: methods and protocols. O'Brien PM, Ed. Totowa, NJ, Humana Press, 2001
42. Zloza A, Sullivan YB, Connick E, Landay AL, Al-Harthi L. CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood 2003;102:2156-2164 (Pubitemid 37122393)
43. Rathanaswami P, Babcook J, Gallo M. High-affinity binding measurements of antibodies to cell-surface-expressed antigens. Anal Biochem 2008;373: 52-60 (Pubitemid 350251324)
44. Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. J Pharm Pharmacol 2008;60:1167-1173
45. Lawrence MC, McKern NM, Ward CW. Insulin receptor structure and its implications for the IGF-1 receptor. Curr Opin Struct Biol 2007;17:699-705 (Pubitemid 350180400)
46. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011;152:2546-2551
47. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38-44 (Pubitemid 351998750)
48. Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010;116:73-78
49. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005;22:359-370 (Pubitemid 40516231)
50. Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978;88:681-695 (Pubitemid 8339956)